Journal Home > Volume 1 , Issue 1
Brain Science Advances 2015, 1(1): 10-16 https://doi.org/10.18679/CN11-6030_R.2015.003
Research Article | Open Access | Issue | Published: 01 September 2015

Fetal stem cells are effective in the treatment of Grade Ⅰ and Ⅱ respiratory failure in amyotrophic lateral sclerosis and muscular dystrophy

Show Author's Information Nataliia S. Sych1( ),  Olena V. Ivankova1,  Mariya O. Klunnyk1,  Iryna G. Matiyashchuk1,  Andrey A. Sinelnyk1,  Mariya P. Demchyk1,  Maryna V. Skalozyb2,  Dario Siniscalco3
Department of Clinical, Cell Therapy Center EmCell, Kiev 02089, Ukraine
Department of Skalozyb-Biotechnology, Cell Therapy Center EmCell, Kiev 04210, Ukraine
Department of Experimental Medicine, Second University of Naples via S. Maria di Costantinopoli 16, Naples 80138, Italy
Keywords:
amyotrophic lateral sclerosis, respiratory failure, fetal stem cells, muscular dystrophy, forced vital capacity, forced expiratory volume
Cite this article:
Sych NS, Ivankova OV, Klunnyk MO, et al. Fetal stem cells are effective in the treatment of Grade Ⅰ and Ⅱ respiratory failure in amyotrophic lateral sclerosis and muscular dystrophy. Brain Science Advances, 2015, 1(1): 10-16. https://doi.org/10.18679/CN11-6030_R.2015.003
Download citation
EndNote(RIS)
BibTeX

379

Views

14

Downloads

Citations

0

Crossref

N/A

WoS

N/A

Scopus

N/A

CSCD

Abstract Full text About this article
Objectives:

To study the effect of fetal stem cell (FSC) therapy on Grade Ⅰ and Ⅱ respiratory failure in patients with amyotrophic lateral sclerosis (ALS) and muscular dystrophy (MD).

Methods:

A comparative study was conducted on 41 patients with Grade Ⅰ or Ⅱ respiratory failure (RF) resulting from ALS or MD. The patients were divided into 4 groups according to the underlying disease and the degree of RF. Patients underwent combined treatment, including the experimental application of FSC therapy, and were examined before FSC treatment, and 6 months and 12 months after treatment.

Results:

FSC treatment improved both subjective and objective breathing parameters as early as 6 months post-treatment. A significant increase in the forced vital capacity (FVC) and forced expiratory volume in 1 second (FEV1) was reported by all patients with Grade Ⅰ RF linked to ALS and MD compared to baseline. Patient respiratory improvement was maintained over the next 6 months. Grade Ⅱ RF patients with MD reported a significant improvement in FVC 12 months after treatment.

Conclusions:

Evidence for respiratory improvement was observed as early as 6 months in all patients after combined treatment including FSC therapy, and this was maintained for a further 6 months after therapy. In MD patients with Grade Ⅱ RF, treatment resulted in a significant FVC and FEV1 increase within 6 months and downgrading to Grade Ⅰ RF within a year after FSC treatment.


menu
Abstract
Full text
Outline
About this article

Fetal stem cells are effective in the treatment of Grade Ⅰ and Ⅱ respiratory failure in amyotrophic lateral sclerosis and muscular dystrophy

Show Author's information Nataliia S. Sych1( ), Olena V. Ivankova1, Mariya O. Klunnyk1, Iryna G. Matiyashchuk1, Andrey A. Sinelnyk1, Mariya P. Demchyk1, Maryna V. Skalozyb2, Dario Siniscalco3
Department of Clinical, Cell Therapy Center EmCell, Kiev 02089, Ukraine
Department of Skalozyb-Biotechnology, Cell Therapy Center EmCell, Kiev 04210, Ukraine
Department of Experimental Medicine, Second University of Naples via S. Maria di Costantinopoli 16, Naples 80138, Italy

Abstract

Objectives:

To study the effect of fetal stem cell (FSC) therapy on Grade Ⅰ and Ⅱ respiratory failure in patients with amyotrophic lateral sclerosis (ALS) and muscular dystrophy (MD).

Methods:

A comparative study was conducted on 41 patients with Grade Ⅰ or Ⅱ respiratory failure (RF) resulting from ALS or MD. The patients were divided into 4 groups according to the underlying disease and the degree of RF. Patients underwent combined treatment, including the experimental application of FSC therapy, and were examined before FSC treatment, and 6 months and 12 months after treatment.

Results:

FSC treatment improved both subjective and objective breathing parameters as early as 6 months post-treatment. A significant increase in the forced vital capacity (FVC) and forced expiratory volume in 1 second (FEV1) was reported by all patients with Grade Ⅰ RF linked to ALS and MD compared to baseline. Patient respiratory improvement was maintained over the next 6 months. Grade Ⅱ RF patients with MD reported a significant improvement in FVC 12 months after treatment.

Conclusions:

Evidence for respiratory improvement was observed as early as 6 months in all patients after combined treatment including FSC therapy, and this was maintained for a further 6 months after therapy. In MD patients with Grade Ⅱ RF, treatment resulted in a significant FVC and FEV1 increase within 6 months and downgrading to Grade Ⅰ RF within a year after FSC treatment.

Keywords: amyotrophic lateral sclerosis, respiratory failure, fetal stem cells, muscular dystrophy, forced vital capacity, forced expiratory volume

References(24)

[1]
Boulis NM, Federici T, Glass JD, Lunn JS, Sakowski SA, Feldman EL. Translational stem cell therapy for amyotrophic lateral sclerosis. Nat Rev Neurol 2011, 8(3): 172-176.
DOI Google Scholar
[2]
Clelland CD, Choi M, Romberg C, Clemenson GDJ, Fragniere A, Tyers P, Jessberger S, Saksida LM, Barker RA, Gage FH. A functional role for adult hippocampal neurogenesis in spatial pattern separation. Science 2009, 325(5937): 210-213.
DOI Google Scholar
[3]
Jessberger S, Nakashima K, Clemenson GDJ, Mejia E, Mathews E, Ure K, Ogawa S, Sinton CM, Gage FH, Hsieh J. Epigenetic modulation of seizure-induced neurogenesis and cognitive decline. J Neurosci 2007, 27(22): 5967-5975.
DOI Google Scholar
[4]
Johnson L, Miller JW, Gkazi AS, Vance C, Topp SD, Newhouse SJ, Al-Chalabi A, Smith BN, Shaw CE. Screening for OPTN mutations in a cohort of British amyotrophic lateral sclerosis patients. Neurobiol Aging 2012, 33(12): 2948.
DOI Google Scholar
[5]
Perlson E, Jeong GB, Ross JL, Dixit R, Wallace KE, Kalb RG, Holzbaur ELF. A switch in retrograde signaling from survival to stress in rapid-onset neurodegeneration. J Neurosci 2009, 29(31): 9903-9917.
DOI Google Scholar
[6]
Péault B, Rudnicki M, Torrente Y, Cossu G, Tremblay J, Partridge T, Gussoni E, Kunkel LM, Huard J. Stem and progenitor cells in skeletal muscle development, maintenance, and therapy. Mol Therapy 2007, 15(5): 867-877.
DOI Google Scholar
[7]
Evtushenko SK, Shaymurzin MR, Evtushenko OS. New modern technology in therapy of neuromuscular diseases for slowing its progression. Int Neurology J 2009, 4(26): 9-18. (in Russian)
Google Scholar
[8]
Ilancheran S, Michalska A, Peh G, Wallace EM, Pera M, Manuelpillai U. Stem cells derived from human fetal membranes display multilineage differentiation potential. Biol Reprod 2007, 77(3): 577-588.
DOI Google Scholar
[9]
Kang PB, Lidov HG, White AJ, Mitchell M, Balasubramanian A, Estrella E, Bennett RR, Darras BT, Shapiro FD, Bambach BJ, Kurtzberg J, Gussoni E, Kunkel LM. Inefficient dystrophin expression after cord blood transplantation in Duchenne muscular dystrophy. Muscle Nerve 2010, 41(6): 746-750.
DOI Google Scholar
[10]
Lawlor MW, Alexander MS, Viola MG, Meng H, Joubert R, Gupta V, Motohashi N, Manfready RA, Hsu CP, Huang P, Bu-Bello A, Kunkel LM, Beggs AH, Gussoni E. Myotubularin-deficient myoblasts display increased apoptosis, delayed proliferation, and poor cell engraftment. Am J Pathol 2012, 181(3): 961-968.
DOI Google Scholar
[11]
Lapan AD, Rozkalne A, Gussoni E. Human fetal skeletal muscle contains a myogenic side population that expresses the melanoma cell-adhesion molecule. Hum Mol Genet 2012, 21(16): 3668-3680.
DOI Google Scholar
[12]
Cossu G, Biressi S. Satellite cells, myoblasts and other occasional myogenic progenitors: Possible origin, phenotypic features and role in muscle regeneration. Semin Cell Dev Biol 2007, 16(4-5): 623-631.
DOI Google Scholar
[13]
Johnson BV, Shindo N, Rathjen PD, Rathjen J, Keough RA. Understanding pluripotency-How embryonic stem cells keep their options open. Mol Hum Reprod 2008, 14(9): 513-520.
DOI Google Scholar
[14]
Knobloch M, Jessberger S. Perspectives on adult neurogenesis. Eur J Nurosci 2011, 33(6): 1013-1017.
DOI Google Scholar
[15]
Acevedo-Arozena A, Kalmar B, Essa S, Ricketts T, Joyce P, Kent R, Rowe C, Parker A, Gray A, Hafezparast M, Thorpe JR, Greensmith L, Fisber EM. A comprehensive assessment of the SOD1G93A low-copy transgenic mouse, which models human amyotrophic lateral sclerosis. Dis Model Mech 2011, 4(5): 686-700.
DOI Google Scholar
[16]
Kukharchuk AL, Radchenko VV. Embryonic progenitor cells, immunological tolerance and aging. Transplantology 2008, 10(1): 51-54.
Google Scholar
[17]
Kim J, Chu JL, Shen XH, Wang JL, Orkin SH. An extended transcriptional network for pluripotency of embryonic stem cells. Cell 2008, 132(6): 1049-1061.
DOI Google Scholar
[18]
Messina G, Biressi S, Monteverde S, Magli A, Cassano M, Perani L, Roncaglia E, Tagliafico E, Starnes L, Campbell CE, Grossi M, Goldhamer DJ, Gronostajski RM, Cossu G. Nfix regulates fetal-specific transcription in developing skeletal muscle. Cell 2010, 140(4): 554-566.
DOI Google Scholar
[19]
Zaporozhan VN, Bazhora YI. Stem Cells. Odessa: Odessa University, 2007, pp. 132-154.
[20]
Zozulya YA, Lysyany NI, Tsymbalyuk VI, et al. Neurogenic Differentiation of Stem Cells. - Kyiv: LLC UIPK. EksOb. 2007: 154-161.
[21]
Miller MR, Hankinson J, Brusasco V, Burgos F, Casaburi R, Coates A, Crapo R, Enright P, van der Grinten CPM, Gustafsson P, et al. Standardisation of spirometry. Eur Respir J 2005, 26(2): 319-338.
Google Scholar
[22]
Bradstreet JJ, Sych N, Antonucci N, Klunnik M, Ivankova O, Matyashchuk I, Demchuk M, Siniscalco D. Efficacy of fetal stem cell transplantation in autism spectrum disorders: an open-labeled pilot study. Cell Transplant 2014, 23(S1): S105-S112.
DOI Google Scholar
[23]
Siniscalco D, Sych N. Regenerative Potential of Stem Cells for Duchenne Muscular Dystrophy. J Regen Med 2013, 2: 2.
Google Scholar
[24]
Sych N, Klunnik M, Ivankova O, Matyaschuk I, Demchuk M, Novytska A, Arkhipenko I, Shalita I, Siniscalco D. Efficacy of fetal stem cells in Duchenne muscular dystrophy therapy. J Neurorestoratol 2014, 2: 37-46.
DOI Google Scholar
Publication history
Copyright
Rights and permissions

Publication history

Received: 20 March 2015
Revised: 20 May 2015
Accepted: 29 May 2015
Published: 01 September 2015
Issue date: September 2015

Copyright

© The authors 2015.

Rights and permissions

This article is published with open access at www.TNCjournal.com

Return